π¨ Big news! Weβre welcoming the @YuvaanTiwari Foundation as a new strategic partner in our fight against #DIPG. Their investment advances GB13 into clinical trials. Together, weβre fighting one of the deadliest pediatric brain cancers with bold science and deep purpose.#DMG
Big news from Targepeutics! The FDA has granted Rare Pediatric Disease designation for our therapy GB13, targeting pediatric diffuse high-grade glioma.
This milestone brings us closer to delivering hope to families. Learn more: https://t.co/C8aEoqrEG7
#RareDisease#DMG#DIPG
Targepeutics is excited for the @FUSFoundation funded research collaboration at @CUAnschutz with @AdamLyonGreen and Mark Borden. Can GB13 be delivered to DIPG tumors via FUS?
Targepeutics is excited for the @FUSFoundation funded research collaboration at @CUAnschutz with @AdamLyonGreen and Mark Borden. Can GB13 be delivered to DIPG tumors via FUS?
"β¨ A huge thank you to @Targetpeutics for being a Silver Sponsor at the #BrainStormSummit! Your support is helping us push the boundaries of innovation and impact. Together, we're making a difference! π‘π#cancelchildhoodcancer
We want to thank Dr. Giselle Sholler @GSholler and the entire @beatccorg team for giving us this opportunity to talk about GB13, our promising lead therapeutic for #DIPG#DMG.
Grateful to the W. W. Smith Trust for funding our project, which will further strengthen our ability to leverage liquid biopsy in identifying candidates for clinical trials and for disease monitoring. Excited for our collaboration with @Targepeutics. @PennStateNSGY#Glioblastoma
#GrayMay is a time to unite with people living with #braintumors & their loved ones to spread awareness about this deadly disease.
Share quick, impactful stats about where we are in our mission to conquer & cure brain tumors, and inspire others to take action this month. #BTAM